AtriCure Q2 revenue $100.9M (+19.4% YoY); net loss narrows to $5.1M, adjusted EBITDA positive $8.0M

AtriCure, Inc.

2023-Q2 EPS reported -$0.25 revenue$194,412,000

Worldwide revenue $100.9M, up 19.4% YoY; U.S. $84.9M (+19.1%), international $16.0M (+20.7%).
Net loss of $5.1M, improvement of $9.7M vs Q2 2022; EPS loss $0.11 vs $0.32.
Gross margin 76.4%, up 130 bps YoY; adjusted EBITDA positive $8.0M, up from -$3.2M.
FY 2023 guidance: revenue $392M-$395M (19-20% growth), adjusted EBITDA ~$12M positive.
Adjusted loss per share guided at $0.92-$0.94 for full year 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AtriCure, Inc. reported the second quarter ended June 30, 2023 results: revenue $100.9 million, net income Net loss of $5.1 million, EPS $0.11. Guidance reaffirmed.

Period: the second quarter ended June 30, 2023
Revenue: $100.9 million
Net income: Net loss of $5.1 million
EPS: $0.11
Guidance: reaffirmed
Result: reported results

Exact text from the filing

in any such filing or document. --- EX-99.1 (EX-99.1) --- For immediate release July 25, 2023 AtriCure Reports Second Quarter 2023 Financial Results • Worldwide revenue of $100.9 million – an increase of 19.4% year over year • U.S. revenue of $84.9 million – an increase of 19.1% year over year • International revenue of $16.0 million – an increase of 20.7% year

View on SEC.gov

Browse all earnings releases →

AtriCure, Inc. filing history →

Source: SEC EDGAR

accession 0001323885-23-000094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.